A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With sJIA
Status:
Recruiting
Trial end date:
2023-08-07
Target enrollment:
Participant gender:
Summary
The reason for this study is to see if the study drug baricitinib is safe and effective in
participants from 1 year to less than 18 years old with systemic juvenile idiopathic
arthritis (sJIA).